Glumetinib clinical trials
Also written SCC244.
Its developmentBy Haihe Biopharma and CSPC Pharmaceutical Group, step by step8 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses glumetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the glumetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 2 |
| 2021 | 2 |
| 2024 | 2 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
Haihe Biopharma Co., Ltd. (5) · Shanghai JMT-Bio Inc. (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Liu Huang (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test glumetinib.
- Dec 2026A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung CancerPhase 2 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Studies
Open first, then newest update. How each study uses glumetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal CancerRecruitingPhase 1/2Liu HuangNCT06980532Written as Glumetinib Combined with FruquintinibHow we know
- A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsRecruitingPhase 3Shanghai JMT-Bio Inc.NCT06829459Written as GlumetinibHow we know
- Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT06908772Written as Glumetinib TabletsHow we know
- A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung CancerNot yet recruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06525350Written as Glumetinib tabletsHow we know
- Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06452433Written as gumarontinibHow we know
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingPhase 1/2Haihe Biopharma Co., Ltd.NCT04270591Written as GlumetinibHow we know
- Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.TerminatedPhase 1/2Shanghai Junshi Bioscience Co., Ltd.NCT04797702Written as Glumetinib combined with ToripalimabHow we know
- A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid TumorsCompletedPhase 1Haihe Biopharma Co., Ltd.NCT03457532Written as Gumarontinib TabletsHow we know
- Study to Evaluate the Safety and Anti-tumor Activity of SCC244CompletedPhase 1Haihe Biopharma Co., Ltd.NCT03466268Written as Gumarontinib TabletsHow we know
- Single Dose Glumetinib in Healthy Chinese Male SubjectsCompletedPhase 1Haihe Biopharma Co., Ltd.NCT05507294Written as GlumetinibHow we know
- Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR InhibitorsStatus unknownPhase 1/2Haihe Biopharma Co., Ltd.NCT04338243Written as GlumetinibHow we know
Given beside what is tested · 1 — glumetinib is usual care or a partner of the new treatment
- Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsRecruitingPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06947291Written as Glumetinib TabletsHow we know